Souhaitez-vous accéder aux communiqués récents ?

Alps Group Inc (Nasdaq: ALPS) appoints former Ernst & Young Partner to its Board of Directors, strengthening governance and capital markets oversight.

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced...

Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Biotechnology for the Non-Biotechnologist (June 10th - June 12th, 2026)" training has been added to ResearchAndMarkets.com's offering.This intensive...

-  Matthew Gall appointed Chief Financial Officer  --  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  - BOSTON, April 15, 2026 (GLOBE...

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead program afimetoran, a potential...

Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Mastering Aseptic Processing for Pharmaceutical & Biotech Manufacturing (Mar 24th - Mar 25th, 2026)" training has been added to ...

Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Best Practices for Supplier Qualification in Life Science (May 6th - May 7th, 2026)" training has been added to ResearchAndMarkets.com's...

SHANGHAI, April 15, 2026 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased...

Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.Obsidian’s lead...

Merakris’ MTX-001 research wins SAWC award; human data show significant wound healing. Phase 2 ongoing with FDA and manufacturing catalysts ahead.